Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Precision Therapeutics to Hold Business Update Conference Call on April 2, 2018
MINNEAPOLIS , March 26, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its
View HTML
Toggle Summary Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with CellBridge Incorporated
MINNEAPOLIS , March 21, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc. , has secured a license agreement with CellBridge Incorporated (“CellBridge”)
View HTML
Toggle Summary Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with 48Hour Discovery
MINNEAPOLIS , March 15, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc. , has secured a license agreement with 48Hour Discovery (“48HD”) which grants it
View HTML
Toggle Summary Precision Therapeutics Increases Equity Stake in Helomics to 25%
MINNEAPOLIS , March 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has converted a previous
View HTML
Toggle Summary Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with SyntArray, LLC
MINNEAPOLIS , March 13, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc. , has secured a license agreement with SyntArray LLC .
View HTML
Toggle Summary Precision Therapeutics Appoints Kevin Hungerford as Vice President of Sales and Marketing
MINNEAPOLIS , March 12, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that it has appointed Kevin Hungerford as Global Vice President of Sales and Marketing, effective immediately.
View HTML
Toggle Summary Precision Therapeutics Forms TumorGenesis Inc. Subsidiary to Focus on the Next Generation of Patient Derived Tumor Models
MINNEAPOLIS , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical (NASDAQ:SKLN), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has formed a wholly
View HTML
Toggle Summary Precision Therapeutics, Formerly Skyline Medical, Announces Stock Ticker Symbol Change to AIPT View HTML
Toggle Summary Skyline Medical Projects 100 STREAMWAY System Sales in the U.S. in 2018
2018 projection would represent a 10x increase over 2017 sales MINNEAPOLIS , Jan. 31, 2018 (GLOBE NEWSWIRE) -- Skyline Medical Inc.  (NASDAQ:SKLN) (“Skyline” or the “Company”), is pleased to announce that it currently projects sales of approximately 100 STREAMWAY Systems in 2018.
View HTML
Toggle Summary Skyline Medical Opens New European Headquarters to Drive International Sales of the STREAMWAY System
Company appoints Jean-Paul Rasschaert as Vice President of International Sales MINNEAPOLIS , Jan. 26, 2018 (GLOBE NEWSWIRE) -- Skyline Medical Inc (NASDAQ:SKLN) (“Skyline” or the “Company”), today announced that it has opened new European headquarters in Belgium and appointed Jean-Paul Rasschaert
View HTML